RHHBY.PK---Sector: Healthcare---Industry: Major Drugs

[setravis]

A 'Pandemic' Now Declared, Focus Back on Swine Flu Stocks
On Friday June 12, 2009, 12:00 pm EDT

The H1N1 virus is officially a pandemic, and vaccine stocks are responding.

Swine flu stocks are up again today, with some extending weekly gains to more than 20%. A number of companies released good news to end the week. From small-cap players to multi-billion dollar giants, shares are up big on high volume. Novartis (NYSE: NVS) announced today that it will have a swine flu vaccine ready by this fall. Shares are up by 4% on the news.

On Thursday, the World Health Organization raised its alert level on the virus to "Phase 6," indicating that it has officially become a pandemic.

As a whole the Swine Flu and Bird Flu Stocks Index is up by 2.5%. It is now beating the S&P 500 by 35.5% over the last month.

Generex Biotechnology (NASDAQ: GNBT) is leading the Index today with 10% gains. The company was granted five new patents for its drug delivery systems. The patents were awarded in Canada, Australia, New Zealand, Brazil, and Lebanon. The stock is still in negative territory this week by -3%.

Sinovac Biotech (AMEX: SVA) is adding another 3% to its industry-leading 30% weekly rally. On Monday the company announced that it had begun production of a swine flu vaccine, and noted that it could produce up to 30 million doses per year.

Vical (NASDAQ: VICL) has fallen from earlier highs, and is now trading up fractionally. Thomas Weisel initiated coverage of the company today with an Overweight rating and a $5 price target. The analyst cited Vical's proprietary technology, strategic partnerships, and licensing agreements.

GlaxoSmithKline (NYSE: GSK) and Hemispherx Biopharma (AMEX: HEB) are both ahead by more than 4% today.

Pure Bioscience (NASDAQ: PURE) and AVI Biopharma (NASDAQ: AVII) are industry laggards today, falling by -3% and -6% respectively.

As of this writing the Swine Flu and Bird Flu Stocks Index is a top-three performing tickerspy Index over the last month, gaining 39.5%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.
http://www.tickerspy.com/index/Swine-Flu-and-Bird-Flu-Stocks?refer=2028Y3


Technicals
13-day EMA Cross Above 50-day MA

Last Price Quote is:
1.98%above 13-day MA
2.09%above 50-day MA
RS Rating: N/A  

Fundamentals
Key Data:
Market Cap (M): $117,170.40  
P/E Ratio: 14.34  
PEG Ratio: N/A  
Next Earnings: N/A
Last Analyst Rating: N/A

Roche sells Tamiflu. Developed and stockpiled for bird flu, world health officials hope it can be effective against the new swine flu outbreak. There's a "run on the bank" for Tamiflu right now.    

[setravis]

Profile: 
     

Roche Holding Ltd. (ADR)
Grenzacherstrasse 124

Basle, 4070
Phone: 41616881111
Fax: 41616919391
Sector: Healthcare
Industry: Major Drugs
Employees: 80,080 
Complete Financials: 12/31/2008
Earnings Announcements: 
Last Updated: Jun 13, 2009 

Business Overview

BRIEF: For the fiscal year ended 31 December 2008, Roche Holding Ltd.'s revenues decreased 1% to SF45.62B. Net income decreased 8% to SF8.97B. Revenues reflects a decrease in sales of the company's products & services in the Pharmaceuticals business division. Net income also reflects higher research & development expenses, an increase in interest cost on defined benefit plans and lower gain on sale of debt securities. http://www.roche.com/

Last Split Date  01/09/2009

[setravis]

Too bad is Roche is fairly illiquid Pink Sheet stock. Still, there's no concern about corporate integrity; it's the largest drug company in Switzerland. Here's a recent article about their pipeline, and what separates them from other pharma companies:
http://www.bloomberg.com/apps/news?pid=newsarchive&sid=a58F9z_Vl8Cc

If it ever upgrades its ADR, the US shares will get an instant boost...